EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc. is showcasing its innovative ExoPTEN therapy, aimed at treating acute spinal cord injuries, at two prestigious September conferences. The company’s CEO will present their research in Boston and participate as a panelist in New York, signifying NurExone’s growing impact in regenerative medicine and exosome technology.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
